Featured Publications
Neoantigens in Patients with De Novo Follicular Lymphoma: Results from the PRIMA Study
Henneges C, Jin D, Venstrom J, Trabucco S, Nielsen T, Penuel E, Huet S, Salles G, Paulson J. Neoantigens in Patients with De Novo Follicular Lymphoma: Results from the PRIMA Study. Blood 2020, 136: 25-26. DOI: 10.1182/blood-2020-134795.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaDe novo diffuse large B-cell lymphomaProgression-free survivalTumor mutational burdenComprehensive genomic profilingCurrent equity holderAssociated with progression-free survivalFollicular lymphomaF. Hoffmann-La RocheFoundation MedicinePrognostic valueClinical outcomesMedian tumor mutation burdenProgression-free survival eventsPooled analysis of patientsLarge B-cell lymphomaResponse to induction treatmentCalculate tumor mutational burdenAssociated with clinical outcomesEZH2 mutation statusComprehensive genomic profiling dataB-cell lymphomaGenetic mutational landscapeAnalysis of patientsProportion of patients
2023
Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab
Nabbi A, Danesh A, Espin-Garcia O, Pedersen S, Wellum J, Fu L, Paulson J, Geoerger B, Marshall L, Trippett T, Rossato G, Pugh T, Hutchinson K. Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab. Nature Cancer 2023, 4: 502-515. PMID: 37038005, PMCID: PMC10132976, DOI: 10.1038/s43018-023-00534-x.Peer-Reviewed Original ResearchConceptsPediatric patientsAssociated with progression-free survivalCD8+ T cellsT cell receptor repertoireProgression-free survivalImmune-checkpoint inhibitionB cell infiltrationTertiary lymphoid structuresBiomarker analysisAtezolizumab therapyAntitumor immunityStable diseasePD-L1Partial responseTumor neoantigensRefractory tumorsPatient tumorsLymphoid structuresT cellsB cellsReceptor repertoireClinical trialsClinical activityTumorImmune response